Literature DB >> 24291238

Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy.

Vincent Donckier1, Valerio Lucidi2, Thierry Gustot3, Christophe Moreno3.   

Abstract

A recent study proposed that liver transplantation may represent life-saving treatment in patients with severe alcoholic hepatitis not responding to medical therapy. In this pilot experience, stringent patient selection resulted in major improvement of short-term survival with low rates of post-transplant alcohol relapse. In the context of organ shortage, which imposes a need for strict selection of transplant candidates, these results raise major ethical questions. Reluctance to perform liver transplantation in alcoholics is based on the fact that alcoholism is frequently considered to be self-inflicted and on fears of harmful post-transplant alcoholism recurrence. A minimal interval of sobriety lasting at least 6 months is a widely adopted criterion for the selection of patients with alcoholic liver disease for liver transplantation. In severe alcoholic hepatitis, the disastrous short-term prognosis in patients not responding to medical therapy does not allow one to reasonably impose an arbitrary period of 6-months of abstinence. This means that these patients must be either systematically excluded from transplantation or selected according to other criteria. Without significant pre-transplant abstinence, it might be argued that these patients do not merit a graft as they have not demonstrated their ability to gain control over their disease through durable modification of their behaviour. Consequently, this procedure could have a negative impact in the public, affecting organ donation and confidence in the fairness of transplant programs. In contrast, ethical principles recommend active treatment of patients, without discrimination, according to the best scientific knowledge. At this stage, we propose that there are no major ethical barriers for further evaluation of this new therapeutic option. The next steps should include transparent communication with the public and further studies to reproduce these results and identify the selection criteria that provide the best long-term outcomes.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol; Early; Ethic; Hepatitis; Severe; Transplantation

Mesh:

Year:  2013        PMID: 24291238     DOI: 10.1016/j.jhep.2013.11.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

1.  Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score.

Authors:  Brian P Lee; Eric Vittinghoff; Christine Hsu; Hyosun Han; George Therapondos; Oren K Fix; David W Victor; Deepti Dronamraju; Gene Y Im; Michael D Voigt; John P Rice; Michael R Lucey; Sheila Eswaran; Po-Hung Chen; Zhiping Li; Haripriya Maddur; Norah A Terrault
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

Review 2.  Ethical issues associated with solid organ transplantation and substance use: a scoping review.

Authors:  Lauren Notini; Denitsa Vasileva; Ani Orchanian-Cheff; Daniel Z Buchman
Journal:  Monash Bioeth Rev       Date:  2019-12

3.  Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis.

Authors:  Brian P Lee; Sumeyye Samur; Ozden O Dalgic; Emily D Bethea; Michael R Lucey; Ethan Weinberg; Christine Hsu; Mary E Rinella; Gene Y Im; Oren K Fix; George Therapondos; Hyosun Han; David W Victor; Michael D Voigt; Sheila Eswaran; Norah A Terrault; Jagpreet Chhatwal
Journal:  Gastroenterology       Date:  2019-04-15       Impact factor: 22.682

4.  Organ Transplantation in the Face of Donor Shortage - Ethical Implications with a Focus on Liver Allocation.

Authors:  Michael Lauerer; Katharina Kaiser; Eckhard Nagel
Journal:  Visc Med       Date:  2016-06-13

5.  Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea.

Authors:  Tae Jin Kwon; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Dong Hyun Sinn; Seung Woon Paik
Journal:  Korean J Transplant       Date:  2021-03-31

6.  Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis.

Authors:  Mohammed Al-Saeedi; Muhammed H Barout; Pascal Probst; Elias Khajeh; Karl Heinz Weiss; Markus K Diener; Arianeb Mehrabi
Journal:  Langenbecks Arch Surg       Date:  2018-10-22       Impact factor: 3.445

7.  Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.

Authors:  Juan P Arab; Daniel Cabrera; Tejasav S Sehrawat; Nidhi Jalan-Sakrikar; Vikas K Verma; Douglas Simonetto; Sheng Cao; Usman Yaqoob; Jonathan Leon; Mariela Freire; Jose I Vargas; Thiago M De Assuncao; Jung H Kwon; Yi Guo; Enis Kostallari; Qing Cai; Tatiana Kisseleva; Youngman Oh; Marco Arrese; Robert C Huebert; Vijay H Shah
Journal:  J Hepatol       Date:  2020-02-20       Impact factor: 25.083

8.  National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States.

Authors:  Brian P Lee; Eric Vittinghoff; Jennifer L Dodge; Giuseppe Cullaro; Norah A Terrault
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

Review 9.  Liver transplantation for alcoholic liver disease: Lessons learned and unresolved issues.

Authors:  José Ursic-Bedoya; Stéphanie Faure; Hélène Donnadieu-Rigole; Georges-Philippe Pageaux
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis.

Authors:  Sumeet K Asrani; James Trotter; Jack Lake; Aijaz Ahmed; Anthony Bonagura; Andrew Cameron; Andrea DiMartini; Stevan Gonzalez; Gene Im; Paul Martin; Philippe Mathurin; Jessica Mellinger; John P Rice; Vijay H Shah; Norah Terrault; Anji Wall; Scott Winder; Goran Klintmalm
Journal:  Liver Transpl       Date:  2020-01       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.